Impax Laboratories Company Profile (NASDAQ:IPXL)

About Impax Laboratories

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: IPXL
  • CUSIP: 45256B10
Key Metrics:
  • Previous Close: $14.60
  • 50 Day Moving Average: $13.21
  • 200 Day Moving Average: $18.65
  • 52-Week Range: $11.65 - $37.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 10.28
  • P/E Growth: 0.89
  • Market Cap: $1.04B
  • Outstanding Shares: 71,330,000
  • Beta: 1.32
Profitability:
  • Net Margins: -19.93%
  • Return on Equity: 11.34%
  • Return on Assets: 5.99%
Debt:
  • Debt-to-Equity Ratio: 0.90%
  • Current Ratio: 2.09%
  • Quick Ratio: 1.59%
Additional Links:
Companies Related to Impax Laboratories:

Analyst Ratings

Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $26.43 (81.02% upside)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
Show:
DateFirmActionRatingPrice TargetDetails
1/17/2017RBC Capital MarketsReiterated RatingSector PerformView Rating Details
1/13/2017BMO Capital MarketsReiterated RatingSell -> Market Perform$18.00View Rating Details
12/28/2016Janney Montgomery ScottInitiated Coverageinit -> Neutral$15.00View Rating Details
12/23/2016Deutsche Bank AGReiterated RatingHold$17.00View Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00View Rating Details
11/10/2016Royal Bank Of CanadaLower Price TargetSector Perform$30.00 -> $18.00View Rating Details
11/7/2016Bank of America CorpDowngradeNeutral -> Underperform$19.00View Rating Details
9/27/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$25.00 -> $26.00View Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00View Rating Details
8/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$40.00 -> $32.00View Rating Details
8/10/2016Leerink SwannLower Price TargetMarket Perform$33.00 -> $24.00View Rating Details
6/1/2016J P Morgan Chase & CoInitiated CoverageNeutral$47.00View Rating Details
4/15/2016BTIG ResearchReiterated RatingBuy$48.00View Rating Details
3/2/2016NomuraReiterated RatingHoldView Rating Details
2/23/2016Susquehanna Bancshares IncLower Price TargetPositive$55.00 -> $43.00View Rating Details
2/17/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformView Rating Details
9/8/2015GuggenheimReiterated RatingBuy$53.50 -> $60.00View Rating Details
4/6/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $56.00View Rating Details
2/25/2015Needham & Company LLCBoost Price TargetBuy$37.00 -> $46.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Impax Laboratories (NASDAQ:IPXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2017        
11/9/2016Q316$0.39$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.12$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.36$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.05$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
Current Year EPS Consensus Estimate: $1.16 EPS
Next Year EPS Consensus Estimate: $1.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.39$0.51$0.45
Q2 20161$0.33$0.33$0.33
Q3 20161$0.38$0.38$0.38
Q4 20161$0.11$0.11$0.11
Q1 20171$0.47$0.47$0.47
Q2 20171$0.49$0.49$0.49
Q3 20171$0.54$0.54$0.54
Q4 20171$0.21$0.21$0.21
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Impax Laboratories (NASDAQ:IPXL)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 84.47%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.52View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
DateHeadline
4-traders.com logoPurcell Julie & Lefkowitz LLP Is Investigating Impax Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (NASDAQ:IPXL)
www.4-traders.com - February 16 at 4:50 PM
News IconImpact of Brokerage Rating on Impax Laboratories, Inc.(IPXL ... - Morning Outlook (NASDAQ:IPXL)
www.morningoutlook.com - February 15 at 8:57 PM
News IconStock Perspective: Impax Laboratories, Inc. (NASDAQ:IPXL ... - Aiken Advocate (NASDAQ:IPXL)
aikenadvocate.com - February 15 at 8:57 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Impax Laboratories, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors (NASDAQ:IPXL)
finance.yahoo.com - February 15 at 8:57 PM
News IconImpax Laboratories, Inc. (IPXL): Analyst Rating Changes and PT Levels - Post Analyst (NASDAQ:IPXL)
postanalyst.com - February 10 at 4:55 AM
realistinvestor.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Is Expected To Post EPS Of $0.61 (NASDAQ:IPXL)
www.realistinvestor.com - February 9 at 6:54 PM
thestreet.com logoCVS Remains Unsure About the Future of Obamacare, CEO Says (NASDAQ:IPXL)
us.rd.yahoo.com - February 9 at 6:54 PM
News IconChecking the Numbers for Impax Laboratories, Inc. (NASDAQ:IPXL) - Midway Monitor (NASDAQ:IPXL)
midwaymonitor.com - February 8 at 11:45 PM
News IconTechnical Levels in Review on Shares of Impax Laboratories Inc. (IPXL) - Benton Bulletin (NASDAQ:IPXL)
bentonbulletin.com - February 8 at 6:44 PM
prnewswire.com logoResearch Reports Coverage on Drug Makers Stocks -- Sanofi, Impax Labs, Heron Therapeutics, and Biostar Pharma - PR Newswire (press release) (NASDAQ:IPXL)
www.prnewswire.com - February 6 at 10:31 AM
finance.yahoo.com logoZacks.com featured highlights: General Motors, Citizens Financial Group, Impax Laboratories and Cosan (NASDAQ:IPXL)
finance.yahoo.com - February 6 at 10:31 AM
News IconImpax Laboratories, Inc. (NASDAQ:IPXL) EPS Analysis - The Newburgh Press (NASDAQ:IPXL)
newburghpress.com - February 4 at 4:38 AM
capitalcube.com logoETFs with exposure to Impax Laboratories, Inc. : February 3, 2017 (NASDAQ:IPXL)
www.capitalcube.com - February 3 at 6:34 PM
realistinvestor.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Mean Rating At $2.7 - RealistInvestor.com (NASDAQ:IPXL)
www.realistinvestor.com - February 3 at 4:45 AM
capitalcube.com logoImpax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : February 2, 2017 (NASDAQ:IPXL)
www.capitalcube.com - February 2 at 6:41 PM
News Icon7 Stocks You Should Sell Right Now (NASDAQ:IPXL)
portal.kiplinger.com - February 2 at 6:41 PM
News IconAverage Directional Index in Review for Impax Laboratories Inc. (IPXL) - Springdale Times (NASDAQ:IPXL)
springdaletimes.com - January 31 at 4:41 AM
News IconCould Impax Laboratories Inc (IPXL) Decrease Even More? The Stock Formed Wedge Down Pattern (NASDAQ:IPXL)
randolphguide.com - January 30 at 11:41 PM
News IconCrunching the Numbers for Impax Laboratories Inc. (IPXL) - Sherwood Daily (NASDAQ:IPXL)
sherwooddaily.com - January 28 at 11:05 PM
finance.yahoo.com logoBlog Coverage Pfizer Reported Positive Results for Mid-stage Trial for C. difficile Vaccine (NASDAQ:IPXL)
finance.yahoo.com - January 27 at 5:01 PM
News IconEarnings in Full Force, Analysts Take Aim at Impax Laboratories, Inc. (NASDAQ:IPXL) - Wall Street Beacon (NASDAQ:IPXL)
wsbeacon.com - January 26 at 7:43 PM
finance.yahoo.com logoImpax to Report Fourth Quarter and Full Year 2016 Results on March 1, 2017 (NASDAQ:IPXL)
finance.yahoo.com - January 25 at 4:49 PM
News IconSharp Decline Puts This Stock at a New Low: Impax Laboratories, Inc. (NASDAQ:IPXL) - Wall Street Beacon (NASDAQ:IPXL)
wsbeacon.com - January 24 at 11:44 PM
News IconInvestor Review: Focusing in on Shares of Impax Laboratories Inc. (IPXL) - Springdale Times (NASDAQ:IPXL)
springdaletimes.com - January 22 at 5:49 PM
News IconWill The Needle Move For Impax Laboratories, Inc. (NASDAQ:IPXL) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:IPXL)
wsbeacon.com - January 20 at 5:49 AM
finance.yahoo.com logoIs Impax a Great Stock for Value Investors? (NASDAQ:IPXL)
finance.yahoo.com - January 19 at 7:46 PM
nasdaq.com logoCommit To Buy Impax Laboratories At $10, Earn 14.1% Annualized Using Options (NASDAQ:IPXL)
www.nasdaq.com - January 12 at 6:26 PM
reuters.com logoCVS slashes price of Impax's EpiPen rival (NASDAQ:IPXL)
www.reuters.com - January 12 at 6:26 PM
marketexclusive.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Regulation FD Disclosure (NASDAQ:IPXL)
marketexclusive.com - January 11 at 11:36 PM
thestreet.com logoBiotech Premarket Movers: IPXL, SGMO, ARLZ (NASDAQ:IPXL)
www.thestreet.com - January 11 at 6:34 PM
biz.yahoo.com logoIMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:IPXL)
biz.yahoo.com - January 11 at 6:34 PM
thestreet.com logoKey Insurer Drops Mylan's EpiPen as Bresch Reflects on Tumultuous 2016 at JPM (NASDAQ:IPXL)
www.thestreet.com - January 11 at 6:34 PM
us.rd.yahoo.com logoFINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Impax Laboratories Inc. (IPXL) and Lead Plaintiff Deadline: January 9, 2017 (NASDAQ:IPXL)
us.rd.yahoo.com - January 9 at 9:47 PM
finance.yahoo.com logoDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Impax Laboratories, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:IPXL)
finance.yahoo.com - January 9 at 4:45 PM
us.rd.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Impax Laboratories Inc. (IPXL) & Lead Plaintiff Deadline: January 9, 2017 (NASDAQ:IPXL)
us.rd.yahoo.com - January 7 at 7:51 PM
prnewswire.com logoImpax Confirms Patent Challenge Relating to Generic Aubagio® (teriflunomide) Tablets, 14 mg (NASDAQ:IPXL)
www.prnewswire.com - January 7 at 5:33 AM
businesswire.com logoIMPAX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuits ... (NASDAQ:IPXL)
www.businesswire.com - January 7 at 5:33 AM
News IconAmedisys to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:IPXL)
www.econotimes.com - January 7 at 12:32 AM
finance.yahoo.com logoIMPAX 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuits Against Impax Laboratories Inc. – IPXL (NASDAQ:IPXL)
finance.yahoo.com - January 7 at 12:32 AM
finance.yahoo.com logoGPM Reminds Investors of the January 9 Deadline in the Class Action Lawsuit Against Impax Laboratories, Inc. (NASDAQ:IPXL)
finance.yahoo.com - January 6 at 6:36 PM
finance.yahoo.com logoUPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Impax Laboratories, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2017 – IPXL (NASDAQ:IPXL)
finance.yahoo.com - January 6 at 6:36 PM
finance.yahoo.com logoBernstein Liebhard LLP Announces That A Suit Has Been Filed Against Impax Laboratories, Inc. (NASDAQ:IPXL)
finance.yahoo.com - January 6 at 6:36 PM
finance.yahoo.com logoFinal Deadline Reminder For Impax Laboratories, Inc. Shareholders - IPXL (NASDAQ:IPXL)
finance.yahoo.com - January 5 at 7:16 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Impax Laboratories Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline (NASDAQ:IPXL)
finance.yahoo.com - January 5 at 7:16 PM
finance.yahoo.com logoJanuary 9 Deadline Alert: Law Offices of Howard G. Smith Reminds Impax Laboratories, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm (NASDAQ:IPXL)
finance.yahoo.com - January 5 at 7:16 PM
finance.yahoo.com logoBragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Impax Laboratories, Inc. (IPXL) and the Lead Plaintiff Deadline of January 9, 2017 (NASDAQ:IPXL)
finance.yahoo.com - January 4 at 9:49 PM
finance.yahoo.com logoImpax to Present at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:IPXL)
finance.yahoo.com - January 4 at 4:45 PM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Impax Laboratories Inc. (IPXL) and Lead Plaintiff Deadline: January 9, 2017 (NASDAQ:IPXL)
finance.yahoo.com - January 4 at 4:45 PM
finance.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Impax Laboratories, Inc. Investors and Encourages Investors to Contact the Firm (NASDAQ:IPXL)
finance.yahoo.com - January 4 at 4:45 PM
marketexclusive.com logoAnalyst Activity – RBC Capital Markets Reiterates Hold on Impax Laboratories (NASDAQ:IPXL) (NASDAQ:IPXL)
marketexclusive.com - January 3 at 4:57 PM

Social

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?

15 brokerages have issued 1-year target prices for Impax Laboratories' stock. Their forecasts range from $15.00 to $48.00. On average, they expect Impax Laboratories' share price to reach $26.43 in the next twelve months.

When will Impax Laboratories announce their earnings?

Impax Laboratories is scheduled to release their next quarterly earnings announcement on Monday, February, 20th 2017.

What are analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

  • According to Zacks Investment Research, "The acquisitions of Tower and Lineage boosted Impax’s branded and generics portfolio. Impax’s generics pipeline should be able to take advantage of the upcoming patent expiries in the pharma industry. The acquisition of several generic products in Aug 2016 further added 18 generic products to the company’s portfolio including 15 currently marketed products thus boding positive for the company.  However, Impax’s Generics segment has been under competitive pressure for Solaraze and Skelaxin, as well as due to lower sales of Adderall XR. Moreover, short-term Albenza supply interruption has impacted results at the Specialty segment. Estimates have been declining ahead of company’s Q4 results. Shares of Impax have underperformed the Generics-Drugs industry in the past one year. " (1/17/2017)

  • BMO Capital Markets analysts commented, "an opportunistic one for IPXL and could drive some upside to our Adrenaclick forecasts." (1/13/2017)

Who owns Impax Laboratories stock?

Impax Laboratories' stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (2.51%), Renaissance Technologies LLC (1.53%), Two Sigma Investments LP (1.49%), NWQ Investment Management Company LLC (1.44%), FMR LLC (0.57%) and Federated Investors Inc. PA (0.40%). Company insiders that own Impax Laboratories stock include Leslie Z Benet, Mark A Schlossberg, Michael Markbreiter, Michael Nestor and Peter R Terreri.

Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Teachers Retirement System of The State of Kentucky, FMR LLC, Thrivent Financial for Lutherans, NWQ Investment Management Company LLC, Pacad Investment Ltd., AQR Capital Management LLC and GSA Capital Partners LLP.

Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?

Impax Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Renaissance Technologies LLC, Federated Investors Inc. PA, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, Lyon Street Capital LLC, Tudor Investment Corp Et Al and Menta Capital LLC.

How do I buy Impax Laboratories stock?

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Impax Laboratories stock cost?

One share of Impax Laboratories stock can currently be purchased for approximately $14.60.

Impax Laboratories (NASDAQ:IPXL) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Earnings History Chart

Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)

Dividend History Chart

Dividend Payments by Quarter for Impax Laboratories (NASDAQ:IPXL)

Last Updated on 2/21/2017 by MarketBeat.com Staff